XML 76 R61.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies - Significant Concentrations (Details)
$ in Thousands
12 Months Ended
Feb. 17, 2014
Mar. 04, 2017
USD ($)
derivative
Feb. 27, 2016
USD ($)
derivative
Feb. 28, 2015
Derivatives        
Number of interest rate swap arrangements or other derivatives held | derivative   0 0  
Retail Pharmacy | Pharmacy sales | Customers | Top five third party payors        
Significant Concentrations        
Percentage of concentration risk   75.60%    
Retail Pharmacy | Pharmacy sales | Customers | Largest third party payor | Express Scripts        
Significant Concentrations        
Percentage of concentration risk     25.30% 27.80%
Retail Pharmacy | Pharmacy sales | Customers | Largest third party payor | Caremark        
Significant Concentrations        
Percentage of concentration risk   27.30%    
Retail Pharmacy | Pharmacy sales | Customers | Medicaid agencies and related managed care Medicaid payors        
Significant Concentrations        
Percentage of concentration risk   19.80%    
Retail Pharmacy | Pharmacy sales | Customers | Largest Medicaid agency        
Significant Concentrations        
Percentage of concentration risk   1.20%    
Retail Pharmacy | Pharmacy sales | Customers | Medicare Part D        
Significant Concentrations        
Percentage of concentration risk   33.00%    
Retail Pharmacy | Purchases | Suppliers | McKesson Corp.        
Significant Concentrations        
Percentage of concentration risk   97.10%    
Period for Purchasing and Delivery Arrangement 5 years      
Pharmacy Services | Medicare Part D        
Significant Concentrations        
Net revenues | $   $ 223,077 $ 162,620  
Percentage of revenues   0.70% 0.50%  
Pharmacy Services | Medicare Part D | Swiss Re        
Significant Concentrations        
Percentage of revenues   50.00%    
Percentage of cost of revenue   50.00%